Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
27
04
2020
accepted:
16
06
2020
pubmed:
23
7
2020
medline:
6
5
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
We compared oncologic outcomes of patients who received neoadjuvant chemotherapy (CT) with those of patients who received neoadjuvant chemotherapy plus chemoradiation (CRT) for resectable gastric adenocarcinoma. We compared oncologic and survival outcomes of patients who received CT or CRT for gastric adenocarcinoma at our institution between July 1995 and July 2018. We analyzed propensity score-matched cohorts based on age, sex, race, tumor histologic characteristics, and clinical stage. We identified 440 patients (mean age 61 ± 12 years, 62% male, 55% white); 345 (78%) received CRT, and 95 (22%) received CT. The propensity score-matched cohorts included 65 patients who received CT and 65 who received CRT. The CRT group had similar frequencies of R1 resection margins to the CT group (7.7% vs. 6.2%, p = 0.75) but significantly higher frequency of pathologic complete response (27.7% vs. 1.5%, p < 0.001). The CRT group had lower pathologic stages (p = 0.002). Median disease-free survival was 50.9 months (95% confidence interval [CI]: 4.7-97.2) in the CT group and 122.1 months (95% CI: 69.0-175.1) in the CRT group (p = 0.07). Median overall survival was 70.7 months (95% CI: 23.9-117.5) in the CT group and 122.1 months (95% CI: 68.7-175.4) in the CRT group (p = 0.21). Compared with CT, CRT for resectable gastric adenocarcinoma is associated with higher rates of pathologic complete response and subsequent lower final pathologic stage, but survival differences are not significant. Ongoing investigation is necessary to better determine the optimal neoadjuvant therapy and identify patients who receive optimal benefit from CRT. III.
Sections du résumé
BACKGROUND
BACKGROUND
We compared oncologic outcomes of patients who received neoadjuvant chemotherapy (CT) with those of patients who received neoadjuvant chemotherapy plus chemoradiation (CRT) for resectable gastric adenocarcinoma.
METHODS
METHODS
We compared oncologic and survival outcomes of patients who received CT or CRT for gastric adenocarcinoma at our institution between July 1995 and July 2018. We analyzed propensity score-matched cohorts based on age, sex, race, tumor histologic characteristics, and clinical stage.
RESULTS
RESULTS
We identified 440 patients (mean age 61 ± 12 years, 62% male, 55% white); 345 (78%) received CRT, and 95 (22%) received CT. The propensity score-matched cohorts included 65 patients who received CT and 65 who received CRT. The CRT group had similar frequencies of R1 resection margins to the CT group (7.7% vs. 6.2%, p = 0.75) but significantly higher frequency of pathologic complete response (27.7% vs. 1.5%, p < 0.001). The CRT group had lower pathologic stages (p = 0.002). Median disease-free survival was 50.9 months (95% confidence interval [CI]: 4.7-97.2) in the CT group and 122.1 months (95% CI: 69.0-175.1) in the CRT group (p = 0.07). Median overall survival was 70.7 months (95% CI: 23.9-117.5) in the CT group and 122.1 months (95% CI: 68.7-175.4) in the CRT group (p = 0.21).
CONCLUSIONS
CONCLUSIONS
Compared with CT, CRT for resectable gastric adenocarcinoma is associated with higher rates of pathologic complete response and subsequent lower final pathologic stage, but survival differences are not significant. Ongoing investigation is necessary to better determine the optimal neoadjuvant therapy and identify patients who receive optimal benefit from CRT.
LEVEL OF EVIDENCE
METHODS
III.
Identifiants
pubmed: 32696305
doi: 10.1245/s10434-020-08864-1
pii: 10.1245/s10434-020-08864-1
pmc: PMC7855908
mid: NIHMS1644468
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
758-765Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009599
Pays : United States
Références
BMC Cancer. 2015 Jul 21;15:532
pubmed: 26194186
Lancet Oncol. 2003 Aug;4(8):498-505
pubmed: 12901965
J Clin Oncol. 2006 Aug 20;24(24):3953-8
pubmed: 16921048
N Engl J Med. 2007 Nov 1;357(18):1810-20
pubmed: 17978289
J Hematol Oncol. 2017 Aug 15;10(1):149
pubmed: 28810883
Ann Surg Oncol. 2017 Aug;24(8):2252-2258
pubmed: 28337660
Cancer. 2018 Mar 1;124(5):998-1007
pubmed: 29393964
N Engl J Med. 2001 Sep 6;345(10):725-30
pubmed: 11547741
Am J Epidemiol. 2010 Nov 1;172(9):1092-7
pubmed: 20802241
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686
Ann Surg Oncol. 2018 Jul;25(7):2012-2017
pubmed: 29748883
BMC Cancer. 2018 Sep 10;18(1):877
pubmed: 30200910
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):660-666
pubmed: 29280460
J Clin Oncol. 2005 Feb 20;23(6):1237-44
pubmed: 15718321
Lancet. 1969 Oct 25;2(7626):865-7
pubmed: 4186452
Gastric Cancer. 2018 Nov;21(6):1004-1013
pubmed: 29730720
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
Clin Transl Oncol. 2006 Aug;8(8):611-5
pubmed: 16952851
J Clin Oncol. 2004 Jul 15;22(14):2774-80
pubmed: 15254045
Gastric Cancer. 2018 Jan;21(1):74-83
pubmed: 28643144
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Oncotarget. 2017 Jul 13;8(46):81430-81440
pubmed: 29113402
Semin Surg Oncol. 2003;21(4):223-7
pubmed: 14648779
Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):741-7
pubmed: 18164837
J Natl Compr Canc Netw. 2016 Oct;14(10):1321-1327
pubmed: 27697984
Ann Surg Oncol. 2017 Sep;24(9):2679-2687
pubmed: 28332034